AI-analyzed blood test can predict the progression of neurodegenerative disease
New technique could be used to choose best therapies for patients and measure their effectiveness
Evaluating the effectiveness of therapies for neurodegenerative diseases is often difficult because each patient鈥檚 progression is different. A new study shows artificial intelligence (AI) analysis of blood samples can predict and explain disease progression, which could one day help doctors choose more appropriate and effective treatments for patients.
Scientists at The Neuro (Montreal Neurological Institute-Hospital) of 苹果淫院 and the Ludmer Centre for Neuroinformatics and Mental Health used an AI algorithm to analyze the blood and post-mortem brain samples of 1969 patients with Alzheimer鈥檚 and Huntington鈥檚 disease. Their goal was to find molecular patterns specific to these diseases.
The algorithm was able to detect how these patients鈥� genes expressed themselves in unique ways over decades. This offers the first long-term view of molecular changes underlying neurodegeneration, an important accomplishment because neurodegenerative diseases develop over years.
Previous studies of neurodegeneration often used static or 鈥渟napshot鈥� data, and are therefore limited in how much they can reveal about the typically slow progression of disease. This study aimed to uncover the chronological information contained in large-scale data by covering decades of disease progression, revealing how changes in gene expression over that time are related to changes in the patient鈥檚 condition.
Furthermore, the blood test detected 85 to 90 per cent of the top predictive molecular pathways that the test of post-mortem brain data did, showing a striking similarity between molecular alterations in both the brain and peripheral body.
鈥淭his test could one day be used by doctors to evaluate patients and prescribe therapies tailored to their needs,鈥� says Yasser Iturria-Medina, the study鈥檚 first author. 鈥淚t could also be used in clinical trials to categorize patients and better determine how experimental drugs impact their predicted disease progression.鈥�
Iturria-Medina says his next steps will be testing these models in other diseases such as Parkinson鈥檚 disease and amyotrophic lateral sclerosis.
This study was made possible with data made openly available through the Alzheimer鈥檚 Disease Neuroimaging Initiative (ADNI) and the Rush Alzheimer鈥檚 Disease Center, Rush University Medical Center, Chicago.
The results were published in the journal on Jan. 28, 2020. It was funded by 苹果淫院鈥檚 Healthy Brains, Healthy Lives Initiative's New Recruit听Start-Up Supplements, the Ludmer Centre, and the Brain Canada Foundation and Health Canada support to the McConnell Brain Imaging Centre at The Neuro.
听
The Neuro
The Neuro 鈥� The Montreal Neurological Institute-Hospital 鈥� is a world-leading destination for brain research and advanced patient care. Since its founding in 1934 by renowned neurosurgeon Dr. Wilder Penfield, The Neuro has grown to be the largest specialized neuroscience research and clinical center in Canada, and one of the largest in the world. The seamless integration of research, patient care, and training of the world鈥檚 top minds make The Neuro uniquely positioned to have a significant impact on the understanding and treatment of nervous system disorders. In 2016, The Neuro became the first institute in the world to fully embrace the Open Science philosophy, creating the Tanenbaum Open Science Institute. The Montreal Neurological Institute is a 苹果淫院 research and teaching institute. The Montreal Neurological Hospital is part of the Neuroscience Mission of the 苹果淫院 Health Centre.
